Market Context — Why This Technology, Why Now

The global demand for blood and blood products consistently outstrips supply, exacerbated by demographic shifts and increasing geopolitical instability. Regulatory bodies are pushing for safer, more accessible medical solutions, while competitive pressures drive innovation towards synthetic alternatives that offer superior shelf-life and reduced immunogenic risks. This technology is poised to meet these challenges by providing a scalable, stable, and safer option for critical care.

Key Competitive Advantages
01

Enhances biocompatibility and safety by reducing immunogenicity and infection risks compared to conventional blood products, improving patient safety.

02

Facilitates large-scale production due to a simplified synthesis process, ensuring stable supply independent of blood donations, even during emergencies.

03

Secured patent registration after overcoming 9 prior art documents and 2 office actions, establishing a clear competitive advantage in the market.

Market Opportunity
Emergency and Disaster Medicine
$200M globally (AI est.)
There is a growing need for rapid response to hemorrhagic shock patients during large-scale disasters and accidents. Conventional blood products have limited stockpiling capacity, creating high demand for alternative technologies.
Emergency medical service providers Disaster relief organizations Government health agencies
Surgical and Intensive Care
$350M globally (AI est.)
Demand for transfusion products is increasing with the rise in surgeries involving blood loss. Reducing transfusion side effect risks and ensuring stable supply directly improves the quality of medical care.
Major hospital networks Surgical device manufacturers Critical care pharmaceutical companies
Developing Nations Healthcare
$1.5B globally (AI est.)
In regions with underdeveloped transfusion systems, room-temperature stable artificial plasma expanders could significantly improve medical access and increase survival rates.
Global health organizations Humanitarian aid suppliers Pharmaceutical companies focused on emerging markets
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a polyoxazoline-conjugated albumin structure, specifically its use as an artificial plasma expander and hemorrhagic shock resuscitation fluid. The claims are robust, having successfully navigated two office actions, indicating a clear and difficult-to-invalidate scope of protection.

Competitive White Space

This patent primarily covers the specific polyoxazoline-albumin conjugate and its use as a plasma expander. White space exists in developing novel drug delivery systems utilizing similar conjugates for targeted therapies, or in exploring other biocompatible polymer-protein combinations for different medical applications like tissue regeneration scaffolds or advanced diagnostics.

Economic Impact
~$100M/year estimated healthcare cost reduction per country (est.).
estimated ROI · USD · AI analysis
ROI Calculation Logic

The domestic blood product market is estimated at ~$10B annually (AI est.). If this technology could replace 5% of existing blood products, it could contribute to an estimated ~$100M (AI est.) in annual healthcare cost reductions. This includes reduced procurement risks through stable supply, optimized storage costs, and decreased expenses for managing side effects (calculated as $10B × 5% × 20% reduction effect).

Speed to Market
3× faster than in-house development
This technology is based on established principles of molecular design and synthesis using existing materials like polyoxazoline and albumin. This could significantly shorten the fundamental research phase compared to starting R&D from scratch. The combination of highly biocompatible materials may also streamline toxicity and safety evaluations, accelerating time-to-market. Adoption could reduce market entry time by approximately 3.5 years.
Competitive Positioning

X: Biocompatibility & Safety
Y: Supply Stability & Preparation Efficiency

Business Models & Applications
💊 Pharmaceutical Manufacturing & Sales
Develop, manufacture, and directly sell artificial plasma expanders or hemorrhagic shock resuscitation fluids to medical institutions as a pharmaceutical company. Significant revenue is anticipated upon market entry after regulatory approval.
🧪 Medical Material & Raw Material Supply
Supply polyoxazoline-conjugated albumin as a high-performance raw material to other pharmaceutical and medical device development companies. Its high biocompatibility supports diverse applied research, contributing to a wide range of industries.
🤝 Technology Licensing
Grant licenses to other companies for manufacturing and sales rights of this patent, limited by region or application. This allows for rapid market expansion and monetization through collaboration with specialized partners or in markets difficult for direct entry.
Adjacent Application Opportunities
🔬 Regenerative Medicine & Tissue Engineering
Cell Culture Scaffolds & Carriers
Leveraging the biocompatibility and stability of polyoxazoline-conjugated albumin, this technology could serve as a scaffold for cell culture or a carrier for cell transport. It has the potential to enhance cell viability and promote differentiation in regenerative medicine, forming a basis for innovative therapeutic development.
💉 Drug Delivery Systems (DDS)
Targeted Drug Delivery Carriers
Combining albumin's drug-binding capacity with polyoxazoline's in-vivo stability, this could be applied as a carrier for efficient, targeted drug delivery to affected areas. It has the potential to reduce side effects and maximize therapeutic efficacy, contributing to the treatment of intractable diseases.
🧪 In Vitro Diagnostics & Reagents
High-Sensitivity Biosensor Materials
The highly biocompatible polyoxazoline-conjugated albumin could be used as a surface modification material for in vitro diagnostics and biosensors. It has the potential to suppress non-specific adsorption and improve detection sensitivity and specificity, aiding early diagnosis and precision medicine.
Integration Roadmap — Estimated 24-Month Deployment
Basic Validation & Formulation Design
Duration: 6 months
Evaluates the technology's characteristics, conducts initial design for formulation, and performs stability tests to establish basic product specifications. Leverages existing knowledge for efficient validation.
Pre-clinical Trials & Mass Production Process Development
Duration: 12 months
Advances safety and efficacy evaluations in animal models, optimizes manufacturing processes, and explores scale-up. Develops with regulatory approval in mind.
Clinical Development Preparation & Regulatory Strategy
Duration: 6 months
Prepares clinical trial protocols, initiates discussions with regulatory authorities, and accelerates preparations for clinical development. Simultaneously, solidifies business partnerships.
Technical Feasibility
The constituent elements—albumin as the core, polyoxazoline as the shell, and a cross-linking agent—exhibit high compatibility with existing biomaterials science and polymer chemistry technologies. The patent claims clearly define these structures, suggesting that manufacturing processes could be established relatively easily by modifying existing biopharmaceutical production facilities or polymer synthesis lines. This could reduce the need for large investments in new specialized equipment, lowering adoption barriers.
Success Scenario
Adopting this technology could enable companies to offer an artificial plasma expander with stable supply, independent of blood donations. This would allow medical institutions to respond rapidly to hemorrhagic shock patients during emergencies and disasters, potentially improving patient survival rates. Additionally, it could reduce storage and distribution costs by an estimated 20% compared to existing blood products.
Patent Record
APPLICATION NO.
特願2021-027892
REGISTRATION NO.
7773169
FILING DATE
2021/02/24
GRANT DATE
2025/11/11
EXPIRATION DATE
2041/02/24
PATENT HOLDER
学校法人　中央大学
Examination History
2023年11月29日
出願審査請求書
2024年12月03日
拒絶理由通知書
2025年01月27日
手続補正書（自発・内容）
2025年01月27日
意見書
2025年05月07日
拒絶理由通知書
2025年07月01日
意見書
2025年07月01日
手続補正書（自発・内容）
2025年10月07日
特許査定